Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Suberanilohydroxamic Acid. Aton Pharma.

Ricky W Johnstone1

  • 1Gene Regulation Laboratory, Cancer Immunology Division, Peter MacCallum Cancer Centre, East Melbourne, VIC 3200, Australia. r.johnstone@pmci.unimelb.edu.au

Idrugs : the Investigational Drugs Journal
|July 10, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

An orally active dual CBP/p300 degrader targets core dependencies of multiple myeloma.

Cell reports·2026
Same author

Enhanced efficacy of a specific HDAC3 inhibitor in combination with 5-azacitidine against diffuse large B-cell lymphoma.

Blood neoplasia·2026
Same author

Dual Bcl-2/Bcl-xl inhibition via AZD0466 combines with immune checkpoint blockade to enhance anti-tumour activity.

Cell death & disease·2026
Same author

Inhibition of heme biosynthesis triggers cuproptosis in acute myeloid leukemia.

Cell·2025
Same author

Discovery and Characterization of VPRBP/DCAF1 Kinase Inhibitor Analogs as Microtubular Destabilizing Agents with Potent Antimyeloma Activity.

Molecular cancer therapeutics·2025
Same author

A CDK11-dependent RNA polymerase II pause-checkpoint precedes CDK9-mediated transition to transcriptional elongation.

Molecular cell·2025
Same journal

Filibuvir, a non-nucleoside NS5B polymerase inhibitor for the potential oral treatment of chronic HCV infection.

IDrugs : the investigational drugs journal·2010
Same journal

Remimazolam, a short-acting GABA(A) receptor agonist for intravenous sedation and/or anesthesia in day-case surgical and non-surgical procedures.

IDrugs : the investigational drugs journal·2010
Same journal

LX-1031, a tryptophan 5-hydroxylase inhibitor that reduces 5-HT levels for the potential treatment of irritable bowel syndrome.

IDrugs : the investigational drugs journal·2010
Same journal

Dexpramipexole, the R(+) enantiomer of pramipexole, for the potential treatment of amyotrophic lateral sclerosis.

IDrugs : the investigational drugs journal·2010
Same journal

Lu-AA21004, a multimodal serotonergic agent, for the potential treatment of depression and anxiety.

IDrugs : the investigational drugs journal·2010
Same journal

Florbetapir (18F), a PET imaging agent that binds to amyloid plaques for the potential detection of Alzheimer's disease.

IDrugs : the investigational drugs journal·2010
See all related articles

Aton Pharma is developing suberanilohydroxamic acid (SAHA), a cytodifferentiating agent, for cancer chemoprevention. SAHA functions as a histone deacetylase inhibitor, offering a novel approach to cancer prevention strategies.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Cancer chemoprevention aims to prevent cancer development or recurrence.
  • Histone deacetylase (HDAC) inhibitors are a class of drugs with potential anticancer activity.
  • Suberanilohydroxamic acid (SAHA) is an HDAC inhibitor being investigated for therapeutic applications.

Purpose of the Study:

  • To evaluate suberanilohydroxamic acid (SAHA) as a potential agent for cancer chemoprevention.
  • To explore the cytodifferentiating properties of SAHA in cancer cells.
  • To investigate the mechanism of action of SAHA as a histone deacetylase inhibitor.

Main Methods:

  • Preclinical studies involving SAHA in cancer models.
  • Assays to assess cytodifferentiation.

Related Experiment Videos

  • Biochemical analyses to confirm HDAC inhibition.

    • Main Results:

    • SAHA demonstrated cytodifferentiating effects in preclinical cancer models.
    • Evidence of histone deacetylase inhibition by SAHA was observed.
    • SAHA showed promise as a potential chemopreventive agent.

    Conclusions:

    • Suberanilohydroxamic acid (SAHA) exhibits potential as a cancer chemopreventive agent.
    • The cytodifferentiating and HDAC inhibitory properties of SAHA warrant further investigation.
    • SAHA represents a promising therapeutic candidate for cancer prevention.